{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:10:51Z","timestamp":1790993451012,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jdsjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Science"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jdermsci.2023.12.008","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T08:15:49Z","timestamp":1704960949000},"page":"86-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["JAK inhibitors for the treatment of vitiligo"],"prefix":"10.1016","volume":"113","author":[{"given":"Shintaro","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoshi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdermsci.2023.12.008_bib1","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41467-019-08337-4","article-title":"Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1034\/j.1600-0749.2003.00032.x","article-title":"Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families","volume":"16","author":"Alkhateeb","year":"2003","journal-title":"Pigment Cell Res."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.det.2016.11.013","article-title":"Genetics of vitiligo","volume":"35","author":"Spritz","year":"2017","journal-title":"Dermatol. Clin."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib5","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/archderm.135.9.1061","article-title":"Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo","volume":"135","author":"Westerhof","year":"1999","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2133.2008.08906.x","article-title":"Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo","volume":"160","author":"Rodr\u00edguez-Mart\u00edn","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamadermatol.2019.0696","article-title":"Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib8","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/s41467-019-09963-8","article-title":"Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo","volume":"10","author":"Tulic","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051040","article-title":"Transcriptome analysis reveals markers of aberrantly activated innate immunity in vitiligo lesional and non-lesional skin","volume":"7","author":"Yu","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/01913123.2022.2044946","article-title":"Melanocytes and keratinocytes morphological changes in vitiligo patients. A histological, immunohistochemical and ultrastructural analysis","volume":"46","author":"Elsherif","year":"2022","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133772","article-title":"Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo","author":"Boukhedouni","year":"2020","journal-title":"JCI Insight 5"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2019.05.011","article-title":"Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo","volume":"139","author":"Chen","year":"2019","journal-title":"Free Rad. Biol. Med."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1755-148X.2011.00920.x","article-title":"Functional defects of peripheral regulatory T lymphocytes in patients with progressive vitiligo","volume":"25","author":"Ahmed","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib16","article-title":"FDA approves Ruxolitinib (Opzelura) for vitiligo therapy: A breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann. Med. Surg. (Lond. )"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.jaad.2019.12.015","article-title":"Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study","volume":"82","author":"Nakagawa","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib18","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib19","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib20","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib22","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s40744-021-00305-z","article-title":"Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 study","volume":"8","author":"Mease","year":"2021","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-023-00764-w","article-title":"Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phase III trials (BRAVE-AA1 and BRAVE-AA2)","volume":"24","author":"Kwon","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib24","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med.."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib25","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med.."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signaling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ad.2020.12.003","article-title":"Janus kinase inhibitors in dermatology: Part 1: General considerations and applications in vitiligo and alopecia Areata","volume":"112","author":"Garcia-Melendo","year":"2021","journal-title":"Actas Dermosifiliogr. (Engl. Ed. )"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib29","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib30","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a Pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/15593258221105370","article-title":"Baricitinib is effective in treating progressing vitiligo in vivo and in vitro","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib32","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib33","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191062","article-title":"Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer","volume":"217","author":"Waldmann","year":"2020","journal-title":"J. Exp. Med"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2340\/00015555-2080","article-title":"Interferon-gamma inhibits melanogenesis and induces apoptosis in melanocytes: A pivotal role of CD8+ cytotoxic T lymphocytes in vitiligo","volume":"95","author":"Yang","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib36","article-title":"Interferon-\u03b3 induces senescence in normal human melanocytes","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119889","article-title":"Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs","volume":"590","author":"Persaud","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib38","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1016\/j.jid.2019.03.1148","article-title":"Oxidative stress-induced HMGB1 release from melanocytes: a paracrine mechanism underlying the cutaneous inflammation in vitiligo","volume":"139","author":"Cui","year":"2019","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/pcmr.12208","article-title":"Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress","volume":"27","author":"Mosenson","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib40","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.0022-202X.2005.23653.x","article-title":"4-Tertiary butyl phenol exposure sensitizes human melanocytes to dendritic cell-mediated killing: relevance to vitiligo","volume":"124","author":"Kroll","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00011-014-0782-9","article-title":"Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo","volume":"64","author":"Tanimoto","year":"2015","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib42","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib44","volume":"8","author":"Chen","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib45","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","article-title":"Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations","volume":"21","author":"McInnes","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib46","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","article-title":"The JAK-Inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: A randomised, controlled, Phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib50","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib51","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jdermsci.2023.12.008_bib53","unstructured":"H. Yamazaki, A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate the safety and efficacy of upadacitinib in subjects with non-Segmental Vitiligo. Japan Registry of Clinical Trials, \u3008https:\/\/rctportal.niph.go.jp\/en\/detail?trial_id=jRCT2031210234\u3009."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib54","unstructured":"United States Food and Drug Administration, FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Accessed Septebmer 1, 2021. 2021; \u3008https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death\u3009."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib55","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaad.2021.09.051","article-title":"Special editorial: when prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration\u2019s September 1, 2021, data safety communication","volume":"86","author":"Murphrey","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib56","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jaad.2022.03.061","article-title":"Reply to: \"Special editorial: when prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration\u2019s September 1, 2021, data safety communication","volume":"87","author":"King","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib57","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib58","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-021-02582-z","article-title":"Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis","volume":"23","author":"Iwamoto","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib59","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/1346-8138.15173","article-title":"Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis","volume":"47","author":"Nakagawa","year":"2020","journal-title":"J. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib60","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00403-022-02343-1","article-title":"Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV-VI","volume":"315","author":"Kim","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib62","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2021.03.028","article-title":"Repigmentation in a patient with vitiligo on crisaborole 2% ointment","volume":"11","author":"Tam","year":"2021","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.jdermsci.2023.12.008_bib63","doi-asserted-by":"crossref","DOI":"10.1111\/dth.14669","article-title":"Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: a comprehensive review","volume":"34","author":"Yazdanian","year":"2021","journal-title":"Dermatol. Ther."}],"container-title":["Journal of Dermatological Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123002712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923181123002712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:31:24Z","timestamp":1729139484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181123002712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0923181123002712"],"URL":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.12.008","relation":{},"ISSN":["0923-1811"],"issn-type":[{"value":"0923-1811","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JAK inhibitors for the treatment of vitiligo","name":"articletitle","label":"Article Title"},{"value":"Journal of Dermatological Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdermsci.2023.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V. on behalf of Japanese Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}